# Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants

> **NCT01437267** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 120 (actual)

## Conditions studied

- Typhoid Fever

## Interventions

- **BIOLOGICAL:** Vi-CRM197 vaccine
- **BIOLOGICAL:** Pneumococcal conjugate vaccine
- **BIOLOGICAL:** Vi Polysaccharide (PS) vaccine

## Key facts

- **NCT ID:** NCT01437267
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2014-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01437267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01437267, "Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01437267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*